Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid-remediable aldosteronism.

Graham T McMahon1, Robert G Dluhy

  • 1Division of Endocrinology, Diabetes & Hypertension, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. gmcmahon@partners.org

Arquivos Brasileiros De Endocrinologia E Metabologia
|March 12, 2005
PubMed
Summary

Glucocorticoid-remediable aldosteronism is a rare genetic condition that causes high blood pressure in children and young adults. It results from a genetic mutation that causes the hormone aldosterone to be made in the wrong part of the adrenal gland. This leads to high blood pressure that doesn't respond to standard treatments. The condition can be diagnosed with a genetic test. Treatment with dexamethasone or mineralocorticoid receptor antagonists can help lower blood pressure. Early diagnosis allows for better treatment and screening of family members to prevent serious complications like cerebral hemorrhage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Professionalism in Continuing Education: Development and Early Outcomes of Accreditation Council for Continuing Medical Education Certificate Assessments.

The Journal of continuing education in the health professions·2026
Same author

When the Algorithm Teaches-Promise and Peril of AI in Physician Learning.

JAMA·2026
Same author

Accredited Continuing Medical Education Delivers: Evidence of Value, Trust, and Impact Across the Healthcare System.

Journal of CME·2025
Same author

Principles to award learning achievements for lifelong learning in health using micro-credentials: an international Delphi study.

Human resources for health·2025
Same author

Transforming Continuing Professional Development for Healthcare Professionals to Meet National Goals in Saudi Arabia.

Journal of CME·2024
Same author

International Medical Graduates and the Physician Workforce.

JAMA·2024

Area of Science:

  • Genetic hypertension research
  • Endocrinology and adrenal disorders
  • Cardiovascular disease mechanisms

Background:

Hypertension in children and young adults remains a diagnostic challenge. While many cases respond to standard therapies, some remain resistant to conventional treatments. One such condition involves abnormal aldosterone production. This hormone typically regulates blood pressure and electrolyte balance. However, in rare cases, its synthesis becomes dysregulated. A genetic mutation leads to aldosterone being produced in the wrong part of the adrenal gland. This misplacement causes persistent high blood pressure. Current diagnostic methods struggle to identify this specific cause. No prior work had resolved the role of ACTH-driven aldosterone synthesis in this context. Understanding this mechanism could improve targeted treatment strategies.

Purpose Of The Study:

This study aims to clarify the pathophysiology of a rare genetic form of hypertension. The condition involves abnormal aldosterone production in the adrenal cortex. Researchers sought to explain why standard antihypertensive drugs often fail in these cases. They also aimed to identify reliable diagnostic and therapeutic approaches. The focus was on how ACTH influences aldosterone synthesis in the wrong adrenal zone. The study examined why hypokalemia only appears in some patients. The goal was to improve early detection and treatment outcomes. This could help prevent complications like cerebral hemorrhage.

Keywords:
Genetic hypertensionAldosterone overproductionAdrenal gland disordersMineralocorticoid receptor antagonists

Frequently Asked Questions

A chimeric gene duplication leads to aldosterone being synthesized in the zona fasciculata under ACTH control.

Because aldosterone overproduction is ACTH-driven, not renin-angiotensin-dependent, ACE inhibitors and beta-blockers fail to lower blood pressure.

Hypokalemia develops only in those treated with potassium-wasting diuretics, not in all patients.

Dexamethasone suppresses ACTH release, reducing aldosterone synthesis and lowering blood pressure.

Spironolactone and eplerenone, mineralocorticoid receptor antagonists, are efficacious in lowering blood pressure.

Related Experiment Videos

Main Methods:

Researchers analyzed a genetic mutation causing a chimeric gene duplication. This duplication leads to aldosterone synthesis in the zona fasciculata. They used genetic testing to confirm the diagnosis in affected individuals. They evaluated the response to dexamethasone in suppressing ACTH release. Blood pressure and potassium levels were monitored in treated patients. Researchers compared the effectiveness of mineralocorticoid receptor antagonists. They tracked outcomes in families with a history of the condition. The study combined clinical data with genetic analysis to validate findings.

Main Results:

The condition was confirmed to result from a chimeric gene duplication. Aldosterone synthesis occurred in the zona fasciculata due to ACTH stimulation. Patients showed resistance to ACE inhibitors and beta-blockers. Hypokalemia developed only in those using potassium-wasting diuretics. Dexamethasone effectively suppressed ACTH and reduced blood pressure. Spironolactone and eplerenone also proved effective in lowering blood pressure. Genetic testing provided a definitive diagnosis in most cases. Early detection allowed targeted treatment and family screening.

Conclusions:

The study supports the role of ACTH-driven aldosterone synthesis in this genetic condition. Genetic testing is a reliable diagnostic tool for this form of hypertension. Treatment with dexamethasone offers both diagnostic and therapeutic benefits. Mineralocorticoid receptor antagonists are also effective in managing symptoms. The condition is associated with a high risk of cerebral hemorrhage. Early diagnosis enables screening of at-risk family members. This improves treatment outcomes and reduces complications. The findings highlight the importance of genetic testing in resistant hypertension.

Early detection allows targeted treatment and screening of at-risk family members to prevent complications.